Mesangial proliferative glomerulonephritis Medical Services in China

Mesangial proliferative glomerulonephritis (MesPGN) is a primary glomerular disease characterized by diffuse or focal hypercellularity of the mesangial area—due to increased mesangial cell number and/or expanded mesangial matrix—without significant endocapillary proliferation, crescent formation, or basement membrane duplication. It is a histopathological diagnosis typically confirmed via renal biopsy and classified under the broader umbrella of IgA nephropathy (IgAN) when immunoglobulin A (IgA) deposits dominate, or as non-IgA MesPGN when other immune complexes (e.g., IgG or IgM) predominate. Pathogenesis involves dysregulated mucosal immunity, abnormal glycosylation of IgA1 leading to autoantibody formation, immune complex deposition in the mesangium, and subsequent activation of complement (particularly the lectin and alternative pathways), triggering local inflammation, mesangial cell activation, cytokine release (e.g., PDGF, TGF-β), and extracellular matrix expansion. This cascade results in progressive glomerular sclerosis and, in some cases, tubulointerstitial fibrosis. Epidemiologically, MesPGN accounts for approximately 10–25% of all native kidney biopsies in East Asia, with higher prevalence in China, Japan, and Korea—likely reflecting both genetic susceptibility (e.g., HLA-DQ/DR variants) and environmental triggers such as recurrent mucosal infections. Globally, it is less common in Caucasian populations (<5% of biopsies). Peak incidence occurs in adolescents and young adults (ages 15–35), with a slight male predominance. Key risk factors include upper respiratory or gastrointestinal infections preceding onset, family history of IgAN or chronic kidney disease, smoking, obesity, uncontrolled hypertension, and persistent microscopic hematuria or proteinuria (>0.5 g/day). While many patients remain stable for years, ~20–30% progress to chronic kidney disease (CKD) stage 3+ over 10–20 years; a subset develops end-stage kidney disease requiring dialysis or transplantation. Quality of life is significantly impacted—not only by physical symptoms (fatigue, edema, hypertension-related headaches, reduced exercise tolerance) but also by psychological burden: anxiety about disease progression, treatment adherence challenges (e.g., long-term corticosteroids or immunosuppressants), dietary restrictions (low-sodium, low-protein), financial strain from repeated monitoring and therapy, and occupational limitations due to fatigue or frequent clinic visits. Patients often report diminished social engagement, sleep disturbances, and reduced health-related quality of life scores on validated instruments (e.g., KDQOL-SF™), particularly in domains of physical functioning, emotional well-being, and symptom burden.

Mesangial proliferative glomerulonephritis (MesPGN) is a histopathologically heterogeneous primary glomerular disease characterized by diffuse or focal mesangial cell hyperplasia and increased mesangial matrix, typically identified on light microscopy. It encompasses a spectrum ranging from mild idiopathic forms to those associated with systemic diseases such as IgA nephropathy (the most common variant), lupus nephritis (Class II), or post-infectious glomerulonephritis. Clinical presentation varies widely—from asymptomatic microscopic hematuria and/or proteinuria to nephrotic-range proteinuria, hypertension, or impaired renal function. Accurate diagnosis requires renal biopsy with integrated evaluation of light microscopy, immunofluorescence, and electron microscopy to distinguish etiologies and guide prognosis and therapy.

Conservative management forms the cornerstone of early or low-risk MesPGN. This includes strict blood pressure control targeting <130/80 mmHg using renin-angiotensin-aldosterone system (RAAS) inhibitors—specifically angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs)—which reduce intraglomerular pressure, attenuate proteinuria, and slow progression of glomerulosclerosis. Dietary modifications are essential: sodium restriction (<2 g/day), moderate protein intake (0.8–1.0 g/kg/day in non-nephrotic patients; lower if GFR <60 mL/min/1.73m²), and avoidance of nephrotoxic agents (e.g., NSAIDs, contrast media). Smoking cessation, weight optimization, and regular monitoring of serum creatinine, estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR), and complement levels (C3, C4) are integral to longitudinal care. In IgA-dominant MesPGN, tonsillectomy may be considered in select endemic regions (e.g., Japan) with recurrent macroscopic hematuria and active mucosal inflammation, though evidence remains limited and controversial outside specific cohorts.

Pharmacologic intervention is stratified by histologic severity, clinical phenotype, and risk of progression. For patients with persistent proteinuria >1 g/day despite 3–6 months of optimized RAAS blockade—and particularly those with crescents, interstitial fibrosis, or declining eGFR—immunosuppression is indicated. First-line regimens include corticosteroids: oral prednisone (0.8–1.0 mg/kg/day for 1–2 months, followed by taper over 4–6 months) or pulse methylprednisolone (500–1000 mg IV × 3 days) in severe presentations. In high-risk IgA nephropathy–associated MesPGN, the combination of corticosteroids plus mycophenolate mofetil (MMF) (0.75–1.0 g twice daily) has demonstrated superior proteinuria reduction and eGFR preservation compared to steroids alone in randomized trials (e.g., TESTING trial, modified protocol). Calcineurin inhibitors (cyclosporine A or tacrolimus) may be used as steroid-sparing agents in refractory cases, though require careful therapeutic drug monitoring due to nephrotoxic potential. Emerging biologics—including targeted-release budesonide (Nefecon®), which delivers corticosteroid selectively to gut-associated lymphoid tissue to modulate aberrant IgA1 production—are now approved in several jurisdictions for primary IgA nephropathy and represent a paradigm shift toward pathophysiology-driven therapy. Rituximab is reserved for rare, autoantibody-mediated or relapsing forms unresponsive to conventional agents. Anticoagulation or antiplatelet therapy is not routinely recommended unless comorbid thrombotic microangiopathy or antiphospholipid syndrome is confirmed.

Surgical treatment plays no primary role in MesPGN. Nephrectomy is contraindicated except in extraordinary circumstances—such as life-threatening hemorrhage from massive cortical necrosis (extremely rare) or end-stage kidney disease (ESKD) requiring transplantation. Kidney transplantation is highly successful in MesPGN, with 5-year graft survival exceeding 90% in most series. However, recurrence rates vary by subtype: ~50% in IgA nephropathy–associated MesPGN (often subclinical), <10% in lupus-related MesPGN, and negligible in idiopathic forms. Pre-transplant evaluation must assess disease activity, cardiovascular risk, and infection screening (especially hepatitis B/C, TB, CMV). Living donor transplantation is preferred when feasible, given shorter wait times and superior outcomes.

China offers distinct advantages in MesPGN management, rooted in its large-scale clinical infrastructure, standardized biopsy protocols, and integration of traditional Chinese medicine (TCM) within evidence-based frameworks. Major academic centers (e.g., Peking University First Hospital, Shanghai Renji Hospital) perform over 10,000 native kidney biopsies annually, enabling rapid histopathologic classification and real-time multidisciplinary review. The Chinese Society of Nephrology’s clinical practice guidelines emphasize individualized immunosuppression based on risk stratification models incorporating Oxford MEST-C scores and genomic biomarkers. Moreover, China leads global research in TCM–allopathy synergy: rigorous RCTs support adjunctive use of Huangkui Capsule (extract of Abelmoschus manihot) and Tripterygium wilfordii polyglycoside (TWP) for reducing proteinuria and stabilizing eGFR, with favorable safety profiles when monitored for hepatotoxicity and gonadal suppression. National health insurance coverage for ACEIs/ARBs, MMF, and newer agents like Nefecon® (recently approved) enhances accessibility. Tele-nephrology platforms facilitate rural follow-up, while AI-assisted pathology tools improve diagnostic consistency across tiered hospitals.

Recovery and long-term prognosis depend critically on adherence and surveillance. Patients should undergo quarterly assessments of UACR, eGFR, and blood pressure; semiannual lipid panels and bone mineral density screening (if on prolonged steroids); and annual ophthalmologic exams. Vaccination against influenza, pneumococcus, and hepatitis B is strongly advised. Physical activity should be encouraged (≥150 min/week moderate aerobic exercise), but contact sports are discouraged during active hematuria or significant proteinuria. Psychosocial support—including counseling and peer networks—is vital, as chronic kidney disease correlates with elevated depression and anxiety prevalence. Pregnancy requires preconception counseling: conception is safe only with stable renal function (eGFR >70 mL/min/1.73m²), proteinuria <1 g/day, and BP <140/90 mmHg on pregnancy-compatible antihypertensives (e.g., labetalol, nifedipine). Finally, patients must understand that MesPGN is often indolent but unpredictable—early intervention, consistent monitoring, and shared decision-making significantly improve 10-year renal survival, with >85% of low-risk patients maintaining eGFR >60 mL/min/1.73m² at decade follow-up.